.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,444,708

« Back to Dashboard

Claims for Patent: 6,444,708

Title: Treatment using venlafaxine
Abstract:This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
Inventor(s): Rudolph; Richard L. (Berwyn, PA), Derivan; Albert T. (Villanova, PA), Upton; G. Virginia (Radnor, PA)
Assignee: Wyeth (Madison, NJ)
Application Number:09/769,998
Patent Claims: 1. A method of treating generalized anxiety disorder in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of the structural formula: ##STR6##

in which A is a moiety of the formula ##STR7##

where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkyl-amino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or when taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is one of the integers 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

2. A method of treating generalized anxiety disorder in a human, the method comprising administering to a human in need thereof an effective amount of a compound of the structural formula: ##STR8##

in which A is a moiety of the formula ##STR9##

where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkyl-amino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or when taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is one of the integers 0, 1, 2,3, or 4;

or a pharmaceutically acceptable salt thereof.

3. A method of treating generalized anxiety disorder in a human, the method comprising administering to a human in need thereof a pharmaceutical composition comprising an effective amount of a compound of the structural formula: ##STR10##

in which A is a moiety of the formula ##STR11##

where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkyl-amino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or when taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is one of the integers 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof, and a carrier.

4. A method according to claim 3 wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.

5. A method according to claim 3 wherein R4 is formyl or alkanoyl of 2 to 7 carbon atoms.

6. A method of treating generalized anxiety disorder in a human, the method comprising administering to a human in need thereof an effective amount of the compound 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

7. A method of treating generalized anxiety disorder in a human, the method comprising administering to a human in need thereof a pharmaceutical composition containing an effective amount of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)-ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof and a carrier.

8. A method according to claim 3, wherein the pharmaceutical composition is in tablet form.

9. A method according to claim 3, wherein the pharmaceutical composition is in capsule form.

10. A method according to claim 1, wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.

11. A method according to claim 1, wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.

12. A method according to claim 1, wherein the effective amount comprises a daily dose of about 75 mg/day.

13. A method according to claim 1, wherein the compound is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride.

14. A method according to claim 1, wherein the compound is (R/S)-1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride.

15. A method of treating generalized anxiety disorder in a human, the method comprising administering orally to a human in need thereof an effective amount of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceuticallly acceptable salt thereof.

16. A method of treating generalized anxiety disorder in a human, the method comprising administering orally to a human in need thereof a pharmaceutical composition containing an effective amount of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or a pharmaceutically acceptable salt thereof, and a carrier.

17. A method according to claim 2, wherein the effective amount comprises a daily dose of between about 50 mg/day to and about 375 mg/day.

18. A method according to claim 2, wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.

19. A method according to claim 2, wherein the effective amount comprises a daily dose of about 75 mg/day.

20. A method of treating generalized anxiety disorder in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutical composition comprising an effective amount of a compound of the structural formula: ##STR12##

in which A is a moiety of the formula ##STR13##

where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkyl-amino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or when taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is one of the integers 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof, and a carrier.

21. A method according to claim 20, wherein the pharmaceutical compositon is in tablet form.

22. A method according to claim 20, wherein the pharmaceutical composition is in capsule form.

23. A method according to claim 2, wherein the compound is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride.

24. A method according to claim 2, wherein the compound is (R/S)-1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc